http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110237064-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-333 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 |
| filingDate | 2019-06-10^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110237064-B |
| titleOfInvention | Use of dicaffeoylquinic acid in preparation of gout medicine |
| abstract | The invention discloses a new use of 1,4-dicaffeoylquinic acid as a xanthine oxidase inhibitor and in the preparation of a medicine for treating gout. In the present invention, a dicaffeoylquinic acid compound is isolated and identified from Artemisia annua leaves for the first time. This compound not only has the activity of inhibiting xanthine oxidase, but also has the function of resisting gout inflammation, and can be better used for treating gout. Dicaffeoylquinic acid is derived from natural plants and has the advantages of being safe, non-toxic, and having few side effects. |
| priorityDate | 2019-06-10^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 122 of 122.